SAR 164653

Drug Profile

SAR 164653

Alternative Names: SAR-164653

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Class Cardiovascular therapies
  • Mechanism of Action Carboxypeptidase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pulmonary hypertension
  • Discontinued Cardiovascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pulmonary-hypertension in USA
  • 31 Mar 2013 Discontinued - Phase-I for Cardiovascular disorders (prevention) in USA (unspecified route)
  • 31 Mar 2013 Phase-I clinical trials in Pulmonary hypertension in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top